<!–

–>

Published on 29/11/2025

Packaging/Artwork Changes: OCR/UDI and Seal Risks

Introduction to Change Control in the Pharmaceutical Sector

The intricacies of pharmaceutical manufacturing demand stringent adherence to regulatory standards to ensure product quality and safety. One critical aspect of this system is the change control process, which governs modifications to products, processes, and equipment. In an environment subject to the stringent scrutiny of regulatory bodies such as the FDA, EMA, and MHRA, pharma professionals must approach change control with diligence and expertise.

This article discusses the importance of change control, focusing on packaging/artwork changes, the role of risk assessments, and the critical distinction between verification and re-validation. Additionally, we will delve into risk thresholds, the utilization of bridging studies, and the necessity for sampling plan updates, encapsulating these concepts in a cohesive framework for effective change management.

The Importance of Risk in Change Control

Change control is a systematic approach to managing modifications, ensuring that any adjustments made do not compromise product quality or regulatory compliance. A core component of this process is risk assessment, which helps identify potential issues that could arise from a proposed change.

Understanding the risk associated with proposed changes is vital, especially when evaluating change control impact assessments. Risk management in change control involves identifying potential hazards, assessing their likelihood and consequences, and determining appropriate mitigation strategies. This proactive approach safeguards not only product integrity but also patient safety.

Regulatory bodies provide guidance on managing these risks. For instance, Annex 15 of the EU GMP guidelines emphasizes the need for thorough change control procedures when implementing changes that could affect product quality.

Steps for Conducting a Change Control Impact Assessment

Conducting an effective change control impact assessment requires a structured approach. Follow these steps to ensure thorough evaluation:

• Step 1: Define the Change – Clearly articulate the proposed change, including the rationale, scope, and specific elements involved.
• Step 2: Gather Input – Engage relevant stakeholders such as quality assurance, regulatory affairs, and production teams to gather diverse perspectives on the proposed change.
• Step 3: Assess Impact – Utilize a risk matrix to evaluate the potential impact of the change on product quality and compliance. Consider factors such as product stability, regulatory commitments, and operational feasibility.
• Step 4: Document Findings – Create a comprehensive report detailing the assessment process, outcomes, and any potential mitigation strategies. Evidence packs should be compiled to support the evaluation.
• Step 5: Review and Approval – Present the findings to the change control board or relevant authorities for review and approval prior to implementation.

By following these steps, pharmaceutical companies can ensure that all changes undergo a thorough impact assessment, reducing the likelihood of negative outcomes and aligning with cGMP expectations.

Verification Versus Re-Validation: Key Distinctions

Within the context of change control, distinguishing between verification and re-validation is crucial. Verification refers to the process of evaluating whether a product or process meets its specified requirements after a change is implemented. In contrast, re-validation involves a comprehensive reassessment of the entire validation status of a process after a significant change has occurred.

This distinction is particularly relevant in the context of packaging and labeling changes. For example, changes in artwork that affect the Unique Device Identification (UDI) may require rigorous verification to confirm that the printed information accurately reflects regulatory requirements and that there are no inaccuracies. In contrast, changes that substantially alter the configuration of a packaging line might necessitate a full re-validation of that process.

To facilitate effective decision-making, organizations must establish clear protocols for determining when verification is sufficient versus when full re-validation is warranted. This protocol should incorporate guidelines from regulatory sources such as 21 CFR Part 211, which outlines expectations for good manufacturing practices.

Risk-Based Change Thresholds in Pharmaceutical Validation

Risk-based change thresholds serve as a guideline to determine the level of scrutiny necessary for various changes. These thresholds categorize changes based on the associated risk to product quality, safety, and regulatory compliance. Implementing such thresholds is instrumental in streamlining change control processes and ensuring resources are allocated wisely.

To establish these thresholds, organizations should consider multiple factors, including:

• Potential Health Impact: Evaluate the possible health risks associated with the change, including effects on product potency, safety, and efficacy.
• Compliance Risk: Examine how the change aligns with regulatory requirements. Compromising regulatory compliance can lead to significant consequences.
• Operational Complexity: Assess whether the implementation of the change adds complexity to operational processes or incurs additional risks that need to be managed.

Once thresholds have been defined, a systematic approach to risk classification can inform the change control process. For instance, low-impact changes could undergo a streamlined assessment, whereas higher-risk changes should involve more extensive investigations and validation activities.

The Role of Bridging Studies in Change Management

Bridging studies play a crucial role in managing changes, particularly when transitioning between different processes, suppliers, or technologies. These studies serve to demonstrate that a new method or process produces results equivalent to those obtained with the existing validated system.

Conducting a bridging study involves several necessary steps:

• Designing the Study: Define the scope of the study, including the parameters to be compared and the acceptance criteria.
• Executing the Study: Carry out the study according to the predefined protocol, ensuring careful data collection and analysis to support the conclusions drawn.
• Evaluating Results: Compare the outcomes against established benchmarks to determine if the new system meets quality standards.
• Documenting and Reporting: Compile the findings in a report that highlights the adequacy of the new process relative to the original.

Bridging studies not only provide evidence of consistency and equivalency but also support the effort to minimize unnecessary re-validation work while ensuring regulatory compliance.

Effectiveness Checks and Periodic Reviews as Part of Change Control

Regular effectiveness checks and periodic reviews are integral to maintaining the integrity of the change control process. These evaluations serve to confirm that implemented changes achieve their intended outcomes and that any potential risks identified during the initial assessment remain controlled.

Incorporate these practices into your organization as follows:

• Effectiveness Checks: Establish a schedule for verifying that the changes implemented are performing as expected. This could involve direct measurement of outcomes, process audits, or feedback from quality assurance personnel.
• Periodic Reviews: Conduct systematic reviews of change control records, impact assessments, and supporting documentation at determined intervals. This review should assess whether previously identified risks have changed over time and if any new risks have emerged.

Adhering to these practices aligns with the regulatory expectations articulated by bodies such as the EMA and ensures that change control remains robust, transparent, and adaptable to evolving regulatory landscapes.

Conclusion

Effective change control is critical to safeguarding product quality and ensuring regulatory compliance in the pharmaceutical sector. By understanding the nuances of risk assessment, verification versus re-validation, and risk thresholds, professionals can develop a robust framework for managing changes related to packaging and artwork, including OCR and UDI considerations. The integration of bridging studies, effectiveness checks, and periodic reviews will further strengthen the change control process, facilitating continuous improvement in a landscape where quality and compliance cannot be compromised.

Pharmaceutical professionals can apply these insights to create a culture of compliance and quality assurance, ultimately enhancing patient safety and contributing to the overall effectiveness of the healthcare system.